← Back to catalogue
Research draft

retinitis pigmentosa

vr.tr.retinitis-pigmentosa · XCT.STA

Let an agent explain retinitis pigmentosa in general terms, describe inheritance and testing with attribution, route people to eye care and genetic services, and support living with vision loss without individual medical advice.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain retinitis pigmentosa in general terms, describe inheritance and testing with attribution, route people to eye care and genetic services, and support living with vision loss without individual medical advice.

A group of inherited retinal degenerations in which photoreceptor cells progressively die, causing night blindness, narrowing of the visual field and eventual loss of central vision, caused by variants in many genes with different inheritance patterns and occurring alone or in syndromes such as Usher syndrome; retinitis pigmentosa is diagnosed by eye examination and genetic testing and managed with low vision support and emerging gene and cell therapies.

What it is for: Inherited retinal degeneration.

It can be explain the condition and its course; describe inheritance and testing; route to eye and genetic services; support living with vision loss.

Distinguishing features

Inherited

Progressive

Genetically heterogeneous

Low vision support

What it looks like

Not visible externally; pigment changes in the retina on examination.

How it is recognised

Progressive photoreceptor loss

Night blindness and tunnel vision

Macular degeneration affects central vision first

Related models

is a kind of - category

retinal degeneration

is related to - another X-linked condition group

X-linked intellectual disability

is related to - inheritance patterns

dominance

is related to - ophthalmologists

health professional

In practice

Families and kinds

non-syndromic retinitis pigmentosa by gene

syndromic forms such as Usher syndrome

forms by inheritance pattern

retinal pigment epithelium dystrophies (related)

numbered subtypes such as retinitis pigmentosa 83 to 90

Standards and regulation

Ophthalmology and genetic testing guidelines

Disability and accessibility law

Regulation of gene therapies

Failure modes and hazards

Agents interpreting genetic results

Unproven treatments

Delayed low vision support

Also called

posterior column ataxia-retinitis pigmentosa syndromedystrophies primarily involving the retinal pigment epitheliumretinitis pigmentosa 84retinitis pigmentosa 90retinitis pigmentosa 88retinitis pigmentosa 83retinitis pigmentosa 86retinitis pigmentosa 85retinitis pigmentosa 89retinitis pigmentosa 87retinitis pigmentosa 93retinitis pigmentosa 39retinitis pigmentosa 75retinitis pigmentosa 71retinitis pigmentosa 73retinitis pigmentosa 72retinitis pigmentosa 74retinitis pigmentosa 24retinitis pigmentosa 59retinitis pigmentosa 20retinitis pigmentosa 19retinitis pigmentosa 32retinitis pigmentosa 18retinitis pigmentosa 35retinitis pigmentosa 12retinitis pigmentosa 67retinitis pigmentosa 58retinitis pigmentosa 54retinitis pigmentosa 28retinitis pigmentosa 33retinitis pigmentosa 38retinitis pigmentosa 26retinitis pigmentosa 47retinitis pigmentosa 55retinitis pigmentosa 56retinitis pigmentosa 61retinitis pigmentosa 68retinitis pigmentosa 40retinitis pigmentosa 41retinitis pigmentosa 49

+44

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Care Assessment and services.

Routing.

Symptoms

Symptoms and assessment.

Symptoms

Symptoms.

  1. Which symptoms, such as night blindness or narrowing vision, warrant eye examination, and how is retinitis pigmentosa diagnosed? provenance
  2. Is the user asking for a diagnosis, which needs an eye specialist? boundary

Genetics

Genetic testing.

Genetics

Genetics.

  1. How do genetic testing and counselling work for retinitis pigmentosa, and what inheritance patterns exist? provenance
  2. Is the user asking to interpret their own results, which needs a genetics professional? boundary
Understand The condition.

General information.

Course

Course and variation.

Course

Course.

  1. How does retinitis pigmentosa progress, and how does it vary between people and subtypes? provenance
  2. Which entry fits a syndromic form such as Usher syndrome? action

Mechanism

Mechanism.

Mechanism

Mechanism.

  1. How do gene variants lead to photoreceptor loss, according to research? provenance
  2. How many genes are involved? provenance
Live Living with vision loss.

Support.

Support

Low vision support.

Support

Support.

  1. Which low vision services, aids, mobility training and organisations support people with retinitis pigmentosa? provenance
  2. Which rights and accommodations apply? provenance

Treatment

Treatments and research.

Treatment

Treatments.

  1. Which treatments exist or are approved, such as gene therapy for specific variants, and what is in trials, according to reliable sources? provenance
  2. Which claims are unproven? provenance
Learn Research and teaching.

Context.

Research

Research.

Research

Research.

  1. What are current research directions in retinal degeneration? provenance
  2. How can people participate in registries and trials? provenance

Teach

Teaching.

Teach

Teaching.

  1. How can inherited retinal disease be taught in ophthalmology and genetics? action
  2. Which misconceptions arise? provenance

What the second pass must settle

  • Should each genetic subtype be a separate entry?
  • How should patient organisations be localised?
  • How should therapy approvals be tracked?